KeithFlahertyMD

Professor, Medicine, Harvard Medical School Director of Developmental Therapeutics, Cancer Center, Massachusetts General Hospital

Join to view full profile

Dr. Flaherty is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Flaherty's full profile

Already have an account?

Office
55 Fruit St
Lawrence House 202
Boston, MA 02114
Phone+1 617-643-5817

Fax+1 617-724-3166
Is this information wrong?

Education & Training

University of Pennsylvania Health SystemFellowship, Hematology and Medical Oncology, 2000 - 2002
Brigham and Women's HospitalResidency, Internal Medicine, 1997 - 2000
Johns Hopkins University School of MedicineClass of 1997

Certifications & Licensure

MA State Medical License 2009 - 2024
FL State Medical License 2015 - 2017
PA State Medical License 2000 - 2010
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

America's Top Doctors Castle Connolly, 2011-2014
Boston Magazine Castle Connolly, 2010-2013
America's Top Doctors for Cancer Castle Connolly, 2010-2013
Elected Member The American Society for Clinical Investigation, 2012
Join now to see all

Clinical Trials

Imatinib Mesylate and Bevacizumab in Treating Patients With Advanced Melanoma or Other Advanced Cancers Start of enrollment: 2003 Oct 01
Completed
Phase 1, Phase 2
Bevacizumab, Sorafenib Tosylate, and Temsirolimus in Treating Patients With Metastatic Kidney Cancer Start of enrollment: 2007 Sep 14
Completed
Phase 2
Sunitinib Before and After Surgery in Treating Patients With Stage IV Kidney Cancer Start of enrollment: 2008 Jun 01
Unknown status
Phase 2
A Study of BBI608 Administered With Paclitaxel in Adult Patients With Advanced Malignancies Start of enrollment: 2011 Apr 01
Completed
Phase 1, Phase 2
Study Comparing the Efficacy of MEK162 Versus Dacarbazine in Unresectable or Metastatic NRAS Mutation-positive Melanoma Start of enrollment: 2013 Jul 12
Completed
Phase 3
Phase I Dose-Escalation, Safety, Pharmacokinetic and Pharmacodynamic Study of BVD-523 in Patients With Advanced Malignancies Start of enrollment: 2013 Mar 01
Completed
Phase 1, Phase 2
LGX818 and MEK162 in Combination With a Third Agent (BKM120, LEE011, BGJ398 or INC280) in Advanced BRAF Melanoma Start of enrollment: 2014 Jul 23
Completed
Phase 2
SX-682 Treatment in Subjects With Metastatic Melanoma Concurrently Treated With Pembrolizumab Start of enrollment: 2019 Jun 12
Recruiting
Phase 1
INCB039110 in Combination With Dabrafenib and Trametinib in Patients With BRAF-mutant Melanoma and Other Solid Tumors. Start of enrollment: 2019 May 29
Terminated
Phase 1
Join now to see all

Publications & Presentations

PubMed

Benefit, recurrence pattern, and toxicity to adjuvant anti-PD-1 monotherapy varies by ethnicity and melanoma subtype: An international multicenter cohort study.
Xue Bai, Aleigha R Lawless, Juliane A Czapla, Stefanie C Gerstberger, Benjamin C Park, Seungyeon Jung, Rebecca Johnson, Naoya Yamazaki, Dai Ogata, Yoshiyasu Umeda, Cai...> ;JAAD International. 2024 Jun 1
Phase II Study of Osimertinib in Patients With Epidermal Growth Factor Receptor Mutations: Results From the NCI-MATCH ECOG-ACRIN (EAY131) Trial Subprotocol E.
Monica F Chen, Zihe Song, Helena A Yu, Lecia V Sequist, Christine M Lovly, Edith P Mitchell, Jeffrey A Moscow, Robert J Gray, Victoria Wang, Lisa M McShane, Larry V Ru...> ;JCO Precision Oncology. 2024 Apr 1
Phase II Study of Erdafitinib in Patients With Tumors WithAmplifications: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol K1.
Jun Gong, Alain C Mita, Zihan Wei, Heather H Cheng, Edith P Mitchell, John J Wright, S Percy Ivy, Victoria Wang, Robert C Gray, Lisa M McShane, Larry V Rubinstein, Dav...> ;JCO Precision Oncology. 2024 Apr 1
Phase II Study of Erdafitinib in Patients With Tumors With Fibroblast Growth Factor Receptor Mutations or Fusions: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131)...
Jun Gong, Alain C Mita, Zihan Wei, Heather H Cheng, Edith P Mitchell, John J Wright, S Percy Ivy, Victoria Wang, Robert C Gray, Lisa M McShane, Larry V Rubinstein, Dav...> ;JCO Precision Oncology. 2024 Apr 1
Phase 1/2 study of combined BCL-xL and MEK inhibition with navitoclax and trametinib in KRAS or NRAS mutant advanced solid tumors.
Corcoran, R., Do, K., Kim, J., Cleary, J., Parikh, A., Yeku, O., Xiong, N., Weekes, C., Veneris, J., Ahronian, L., Mauri, G., Tian, J., Norden, B., Michel, A., Van Sev...> ;Clinical Cancer Research. 2024 Mar 8
Trastuzumab and Pertuzumab in Patients with Non-Breast/Gastroesophageal HER2-Amplified Tumors: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol J.
Roisin M Connolly, Victoria Wang, David M Hyman, Petros Grivas, Edith P Mitchell, John J Wright, Elad Sharon, Robert J Gray, Lisa M McShane, Larry V Rubinstein, David ...> ;Clinical Cancer Research. 2024 Apr 1
Disrupting CD38-driven T cell dysfunction restores sensitivity to cancer immunotherapy.
Or-Yam Revach, Angelina M Cicerchia, Ofir Shorer, Boryana Petrova, Seth Anderson, Joshua Park, Lee Chen, Arnav Mehta, Samuel J Wright, Niamh McNamee, Aya Tal-Mason, Gi...> ;Biorxiv. 2024 Mar 26
2 citations
MAESTRO-Pool Enables Highly Parallel and Specific Mutation-Enrichment Sequencing for Minimal Residual Disease Detection in Cohort Studies.
Timothy Blewett, Justin Rhoades, Ruolin Liu, Kan Xiong, Sainetra Sridhar, Andjela Crnjac, Ju Cheng, Aleigha R Lawless, Dennie T Frederick, Keith T Flaherty, Gerassimos...> ;Clinical Chemistry. 2024 Feb 7
1 citations
A twenty year perspective on melanoma therapy.
Keith T Flaherty> ;Pigment Cell & Melanoma Research. 2023 Nov 1
2 citations
Contribution of MEK Inhibition to BRAF/MEK Inhibitor Combination Treatment of-Mutant Melanoma: Part 2 of the Randomized, Open-Label, Phase III COLUMBUS Trial.
Paolo A Ascierto, Reinhard Dummer, Helen J Gogas, Ana Arance, Mario Mandala, Gabriella Liszkay, Claus Garbe, Dirk Schadendorf, Ivana Krajsova, Ralf Gutzmer, Vanna Chia...> ;Journal of Clinical Oncology. 2023 Oct 10
2 citations
Targeting Upregulated cIAP2 in SOX10-Deficient Drug Tolerant Melanoma.
McKenna Q Glasheen, Signe Caksa, Amelia G Young, Nicole A Wilski, Connor A Ott, Inna Chervoneva, Keith T Flaherty, Meenhard Herlyn, Xiaowei Xu, Andrew E Aplin, Claudia...> ;Molecular Cancer Therapeutics. 2023 Sep 5
13 citations
The NCI-MATCH trial: lessons for precision oncology.
Peter J O'Dwyer, Robert J Gray, Keith T Flaherty, Alice P Chen, Shuli Li, Victoria Wang, Lisa M McShane, David R Patton, James V Tricoli, P Mickey Williams, A John Iaf...> ;Nature Medicine. 2023 Jun 1
3 citations
Phase II Study of Palbociclib (PD-0332991) in CCND1, 2, or 3 Amplification: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1B.
Clark, A., Hong, F., Finn, R., DeMichele, A., Mitchell, E., Zwiebel, J., Arnaldez, F., Gray, R., Wang, V., McShane, L., Rubinstein, L., Patton, D., Williams, P., Hamil...> ;Clinical Cancer Research. 2023 Apr 14
Author Correction: Reversal of pre-existing NGFR-driven tumor and immune therapy resistance.
Julia Boshuizen, David W Vredevoogd, Oscar Krijgsman, Maarten A Ligtenberg, Stephanie Blankenstein, Beaunelle de Bruijn, Dennie T Frederick, Juliana C N Kenski, Mara P...> ;Nature Communications. 2023 Feb 7
6 citations
Discovery of Targets for Immune-Metabolic Antitumor Drugs Identifies Estrogen-Related Receptor Alpha.
Avinash Sahu, Xiaoman Wang, Phillip Munson, Jan P G Klomp, Xiaoqing Wang, Shengqing Stan Gu, Ya Han, Gege Qian, Phillip Nicol, Zexian Zeng, Chenfei Wang, Collin Tokhei...> ;Cancer Discovery. 2023 Mar 1
12 citations
National Cancer Institute Combination Therapy Platform Trial with Molecular Analysis for Therapy Choice (ComboMATCH).
Funda Meric-Bernstam, James M Ford, Peter J O'Dwyer, Geoffrey I Shapiro, Lisa M McShane, Boris Freidlin, Roisin E O'Cearbhaill, Suzanne George, Julia Glade-Bender, Gar...> ;Clinical Cancer Research. 2023 Apr 14
26 citations
Targeting TBK1 to overcome resistance to cancer immunotherapy.
Yi Sun, Or-Yam Revach, Seth Anderson, Emily A Kessler, Clara H Wolfe, Anne Jenney, Caitlin E Mills, Emily J Robitschek, Thomas G R Davis, Sarah Kim, Amina Fu, Xiang Ma...> ;Nature. 2023 Mar 1
36 citations
Myeloid-derived itaconate suppresses cytotoxic CD8T cells and promotes tumour growth.
Hongyun Zhao, Da Teng, Lifeng Yang, Xincheng Xu, Jiajia Chen, Tengjia Jiang, Austin Y Feng, Yaqing Zhang, Dennie T Frederick, Lei Gu, Li Cai, John M Asara, Marina Pasc...> ;Nature Metabolism. 2022 Dec 1
15 citations
Clinical Activity of Mitogen-Activated Protein Kinase-Targeted Therapies in Patients With Non-V600 BRAF-Mutant Tumors.
Matthew Dankner, Yifan Wang, Rouhi Fazelzad, Benny Johnson, Caroline A Nebhan, Ibiayi Dagogo-Jack, Nathaniel J Myall, Georg Richtig, Jillian W P Bracht, Marco Gerlinge...> ;JCO Precision Oncology. 2022 Aug 1
40 citations
COLUMBUS 5-Year Update: A Randomized, Open-Label, Phase III Trial of Encorafenib Plus Binimetinib Versus Vemurafenib or Encorafenib in Patients WithV600-Mutant Melanoma.
Reinhard Dummer, Keith T Flaherty, Caroline Robert, Ana Arance, Jan Willem B de Groot, Claus Garbe, Helen J Gogas, Ralf Gutzmer, Ivana Krajsová, Gabriella Liszkay, Car...> ;Journal of Clinical Oncology. 2022 Dec 20
23 citations
HRS phosphorylation drives immunosuppressive exosome secretion and restricts CD8T-cell infiltration into tumors.
Lei Guan, Bin Wu, Ting Li, Lynn A Beer, Gaurav Sharma, Mingyue Li, Chin Nien Lee, Shujing Liu, Changsong Yang, Lili Huang, Dennie T Frederick, Genevieve M Boland, Guan...> ;Nature Communications. 2022 Jul 14
6 citations
Phase II Study of Afatinib in Patients With Tumors With Human Epidermal Growth Factor Receptor 2-Activating Mutations: Results From the National Cancer Institute-Molec...
Philippe L Bedard, Shuli Li, Kari B Wisinski, Eddy S Yang, Sewanti A Limaye, Edith P Mitchell, James A Zwiebel, Jeffrey A Moscow, Robert J Gray, Victoria Wang, Lisa M ...> ;JCO Precision Oncology. 2022 Jul 1
10 citations
Spartalizumab or placebo in combination with dabrafenib and trametinib in patients withV600-mutant melanoma: exploratory biomarker analyses from a randomized phase 3 t...
Hussein A Tawbi, Caroline Robert, Jan C Brase, Daniel Gusenleitner, Eduard Gasal, James Garrett, Alexander Savchenko, Güllü Görgün, Keith T Flaherty, Antoni Ribas, Rei...> ;Journal for Immunotherapy of Cancer. 2022 Jun 1
4 citations
Targeting wild-type TP53 using AMG 232 in combination with MAPK inhibition in Metastatic Melanoma; a phase 1 study.
Stergios J Moschos, Shahneen Sandhu, Karl D Lewis, Ryan J Sullivan, Igor Puzanov, Douglas B Johnson, Haby A Henary, Hansen Wong, Vijay V Upreti, Georgina V Long, Keith...> ;Investigational New Drugs. 2022 Oct 1
11 citations
Antitumor Activity of a Mitochondrial-Targeted HSP90 Inhibitor in Gliomas.
Shiyou Wei, Delong Yin, Shengnan Yu, Xiang Lin, Milan R Savani, Kuang Du, Yin Ku, Di Wu, Shasha Li, Hao Liu, Meng Tian, Yaohui Chen, Michelle Bowie, Seethalakshmi Hari...> ;Clinical Cancer Research. 2022 May 13
Join now to see all

Journal Articles

Effect of Capivasertib in Patients with an AKT1 E17K-Mutated Tumor
Kevin Kalinsky, Edith P Mitchell, Barbara A Conley, Lyndsay N Harris, Carlos L Arteaga, Alice P Chen, Keith T Flaherty, JAMA Oncology
Publisher Correction: Robust Prediction of Response to Immune Checkpoint Blockade Therapy in Metastatic Melanoma
Genevieve Boland, Ryan J Sullivan, Keith Flaherty, Nature
A PAX3/BRN2 Rheostat Controls the Dynamics of BRAF Mediated MITF Regulation in MITFhigh/AXLlow Melanoma
Keith T Flaherty, Jennifer A Wargo, Wiley
Robust Prediction of Response to Immune Checkpoint Blockade Therapy in Metastatic Melanoma
Ryan J Sullivan, Genevieve Boland, Keith Flaherty, Nature
When Tissue Is No Longer the Issue: Tissue-Agnostic Cancer Therapy Comes of Age
Keith Flaherty, MD, Annals of Internal Medicine
Join now to see all

Lectures

Tissue Agnostic Drug Development Operational and Scientific Challenges. Tissue Agnostic Drug Development
2018 ASCO Annual Meeting - Chicago, Illinois - 05/31/2018

Press Mentions

AACR Names Fellows of the AACR Academy Class of 2023April 7th, 2023
AACR Announces Fellows of the AACR Academy Class of 2023 and New AACR Academy PresidentApril 6th, 2023
NaNotics to Collaborate with Mass General Cancer Center on Novel NanomedicineSeptember 9th, 2022
Join now to see all